Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.

Immunologic research - 1 Aug 2011

Yu Ling, Favoino Elvira, Wang Yangyang, Ma Yang, Deng Xiaojuan, Wang Xinhui

Abstract excerpt

PLX4032 is a BRAF-selective inhibitor shown to be efficacious in the treatment of melanomas presenting with the BRAF(V600E) mutation. However, favorable responses to treatment are short-lived, and complete remission is rarely observed. Therefore, it is important to identify novel therapies designed to enhance treatment responses and to increase the longevity of initial response to BRAF inhibitors. To this end, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Chondroitin Sulfate Proteoglycans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Drug Synergism

Share to Indoles

Share to Melanoma

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 21717063
DOI: 10.1007/s12026-011-8232-z

Genes

BRAF
CSPG4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.PMID 21717063Read ↗

A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.Semantic proximity Read ↗

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.Semantic proximity Read ↗

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant MelanomaSemantic proximity Read ↗

Targeting BRAF in advanced melanoma: a first step toward manageable disease.Semantic proximity Read ↗

Multiple murine BRaf<sup>V600E</sup> melanoma cell lines with sensitivity to PLX4032Semantic proximity Read ↗

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.Semantic proximity Read ↗

Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma.Semantic proximity Read ↗

Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.Semantic proximity Read ↗

[Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].Semantic proximity Read ↗

Inhibition of mutated, activated BRAF in metastatic melanoma.Semantic proximity Read ↗

Exogenous Recombinant N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B; ARSB) Inhibits Progression of B16F10 Cutaneous Melanomas and Modulates Cell SignalingSemantic proximity Read ↗

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.